Analysis of methods commonly used for glycopeptide and oxazolidinone susceptibility testing in Enterococcus faecium isolates
The susceptibility to teicoplanin, vancomycin and linezolid of 30 clinical isolates of Enterococcus faecium was tested by Vitek 2, Phoenix, Etest, broth microdilution and disc diffusion tests. The vanA and vanB resistance genes and the 23S rRNA gene G2576T mutation were detected by PCR and PCR-RFLP,...
Gespeichert in:
| Veröffentlicht in: | Journal of medical microbiology 2010-06, Vol.59 (6), p.672-678 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 678 |
|---|---|
| container_issue | 6 |
| container_start_page | 672 |
| container_title | Journal of medical microbiology |
| container_volume | 59 |
| creator | RAPONI, Giammarco CRISTINA GHEZZI, Maria GHERARDI, Giovanni LORINO, Giulia DICUONZO, Giordano |
| description | The susceptibility to teicoplanin, vancomycin and linezolid of 30 clinical isolates of Enterococcus faecium was tested by Vitek 2, Phoenix, Etest, broth microdilution and disc diffusion tests. The vanA and vanB resistance genes and the 23S rRNA gene G2576T mutation were detected by PCR and PCR-RFLP, respectively. Resistance rates to teicoplanin ranged from 3% for Vitek 2 to 57.6% for the Phoenix test, and those to vancomycin ranged from 56.7% for Vitek 2 to 86.7% for the Phoenix test. Only two out of 25 strains carrying the vanA gene were univocally recognized as the VanA phenotype. The only strain with the G2576T mutation did not carry the vanA gene and showed resistance to linezolid by the disc diffusion, Vitek 2 and broth dilution methods (MIC>8 microg ml(-1)), but was susceptible when tested with the Phoenix test and Etest (MIC |
| doi_str_mv | 10.1099/jmm.0.016444-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733118058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733118058</sourcerecordid><originalsourceid>FETCH-LOGICAL-c364t-1d29977ea06755adaf4f1aeef5a921518748b82d8097abaa3a46131c5510be0e3</originalsourceid><addsrcrecordid>eNpFkElrHDEQRoVJsMfLNcegS_Cpx6VWq5ejMY5tMOSSnEW1FkdGy6TVDWmTH2-ZGcenoqhXHx-PkC8MtgyG4eo5hC1sgbVN01RwRDas6XglyvqJbADquqpbJk7Iac7PAKzjfDgmJzWwXggBG_LvOqJfs8s0WRrM_DvpTFUKIUW_0iUbTW2a6JNfVdqZ3ey0oRg1TX_xJXmnXUzR0Lxk9XYcnXfzSmeTZxefqIv0Ns5mSioptWRq0Si3BOpy8ligc_LZos_m4jDPyK_vtz9v7qvHH3cPN9ePleJtM1dM18PQdQah7YRAjbaxDI2xAoeaCdZ3TT_2te5h6HBE5Ni0jDMlBIPRgOFn5HKfu5vSn6WUk8GVwt5jNGnJslhhrAfRF3K7J9WUcp6MlbvJBZxWyUC-CZdFuAS5Fy6hPHw9RC9jMPo__m64AN8OAGaF3k4YlcsfXN2LruUtfwWjzoxZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733118058</pqid></control><display><type>article</type><title>Analysis of methods commonly used for glycopeptide and oxazolidinone susceptibility testing in Enterococcus faecium isolates</title><source>MEDLINE</source><source>Microbiology Society</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>RAPONI, Giammarco ; CRISTINA GHEZZI, Maria ; GHERARDI, Giovanni ; LORINO, Giulia ; DICUONZO, Giordano</creator><creatorcontrib>RAPONI, Giammarco ; CRISTINA GHEZZI, Maria ; GHERARDI, Giovanni ; LORINO, Giulia ; DICUONZO, Giordano</creatorcontrib><description>The susceptibility to teicoplanin, vancomycin and linezolid of 30 clinical isolates of Enterococcus faecium was tested by Vitek 2, Phoenix, Etest, broth microdilution and disc diffusion tests. The vanA and vanB resistance genes and the 23S rRNA gene G2576T mutation were detected by PCR and PCR-RFLP, respectively. Resistance rates to teicoplanin ranged from 3% for Vitek 2 to 57.6% for the Phoenix test, and those to vancomycin ranged from 56.7% for Vitek 2 to 86.7% for the Phoenix test. Only two out of 25 strains carrying the vanA gene were univocally recognized as the VanA phenotype. The only strain with the G2576T mutation did not carry the vanA gene and showed resistance to linezolid by the disc diffusion, Vitek 2 and broth dilution methods (MIC>8 microg ml(-1)), but was susceptible when tested with the Phoenix test and Etest (MIC<or=4 microg ml(-1)). Therefore, the resistance to glycopeptides and linezolid was not univocally detected by the susceptibility testing methods used in this study.</description><identifier>ISSN: 0022-2615</identifier><identifier>EISSN: 1473-5644</identifier><identifier>DOI: 10.1099/jmm.0.016444-0</identifier><identifier>PMID: 20185550</identifier><identifier>CODEN: JMMIAV</identifier><language>eng</language><publisher>Reading: Society for General Microbiology</publisher><subject>Acetamides - pharmacology ; Anti-Bacterial Agents - pharmacology ; Bacterial Proteins - genetics ; Bacteriology ; Biological and medical sciences ; Carbon-Oxygen Ligases - genetics ; DNA, Bacterial - genetics ; Enterococcus faecium - drug effects ; Fundamental and applied biological sciences. Psychology ; Glycopeptides - pharmacology ; Humans ; Infectious diseases ; Linezolid ; Medical sciences ; Microbial Sensitivity Tests - methods ; Microbiology ; Miscellaneous ; Oxazolidinones - pharmacology ; Polymerase Chain Reaction ; Polymorphism, Restriction Fragment Length ; RNA, Ribosomal, 23S - genetics ; Teicoplanin - pharmacology ; Vancomycin - pharmacology</subject><ispartof>Journal of medical microbiology, 2010-06, Vol.59 (6), p.672-678</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c364t-1d29977ea06755adaf4f1aeef5a921518748b82d8097abaa3a46131c5510be0e3</citedby><cites>FETCH-LOGICAL-c364t-1d29977ea06755adaf4f1aeef5a921518748b82d8097abaa3a46131c5510be0e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,3733,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22857636$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20185550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RAPONI, Giammarco</creatorcontrib><creatorcontrib>CRISTINA GHEZZI, Maria</creatorcontrib><creatorcontrib>GHERARDI, Giovanni</creatorcontrib><creatorcontrib>LORINO, Giulia</creatorcontrib><creatorcontrib>DICUONZO, Giordano</creatorcontrib><title>Analysis of methods commonly used for glycopeptide and oxazolidinone susceptibility testing in Enterococcus faecium isolates</title><title>Journal of medical microbiology</title><addtitle>J Med Microbiol</addtitle><description>The susceptibility to teicoplanin, vancomycin and linezolid of 30 clinical isolates of Enterococcus faecium was tested by Vitek 2, Phoenix, Etest, broth microdilution and disc diffusion tests. The vanA and vanB resistance genes and the 23S rRNA gene G2576T mutation were detected by PCR and PCR-RFLP, respectively. Resistance rates to teicoplanin ranged from 3% for Vitek 2 to 57.6% for the Phoenix test, and those to vancomycin ranged from 56.7% for Vitek 2 to 86.7% for the Phoenix test. Only two out of 25 strains carrying the vanA gene were univocally recognized as the VanA phenotype. The only strain with the G2576T mutation did not carry the vanA gene and showed resistance to linezolid by the disc diffusion, Vitek 2 and broth dilution methods (MIC>8 microg ml(-1)), but was susceptible when tested with the Phoenix test and Etest (MIC<or=4 microg ml(-1)). Therefore, the resistance to glycopeptides and linezolid was not univocally detected by the susceptibility testing methods used in this study.</description><subject>Acetamides - pharmacology</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Bacterial Proteins - genetics</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>Carbon-Oxygen Ligases - genetics</subject><subject>DNA, Bacterial - genetics</subject><subject>Enterococcus faecium - drug effects</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glycopeptides - pharmacology</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Linezolid</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests - methods</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Oxazolidinones - pharmacology</subject><subject>Polymerase Chain Reaction</subject><subject>Polymorphism, Restriction Fragment Length</subject><subject>RNA, Ribosomal, 23S - genetics</subject><subject>Teicoplanin - pharmacology</subject><subject>Vancomycin - pharmacology</subject><issn>0022-2615</issn><issn>1473-5644</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkElrHDEQRoVJsMfLNcegS_Cpx6VWq5ejMY5tMOSSnEW1FkdGy6TVDWmTH2-ZGcenoqhXHx-PkC8MtgyG4eo5hC1sgbVN01RwRDas6XglyvqJbADquqpbJk7Iac7PAKzjfDgmJzWwXggBG_LvOqJfs8s0WRrM_DvpTFUKIUW_0iUbTW2a6JNfVdqZ3ey0oRg1TX_xJXmnXUzR0Lxk9XYcnXfzSmeTZxefqIv0Ns5mSioptWRq0Si3BOpy8ligc_LZos_m4jDPyK_vtz9v7qvHH3cPN9ePleJtM1dM18PQdQah7YRAjbaxDI2xAoeaCdZ3TT_2te5h6HBE5Ni0jDMlBIPRgOFn5HKfu5vSn6WUk8GVwt5jNGnJslhhrAfRF3K7J9WUcp6MlbvJBZxWyUC-CZdFuAS5Fy6hPHw9RC9jMPo__m64AN8OAGaF3k4YlcsfXN2LruUtfwWjzoxZ</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>RAPONI, Giammarco</creator><creator>CRISTINA GHEZZI, Maria</creator><creator>GHERARDI, Giovanni</creator><creator>LORINO, Giulia</creator><creator>DICUONZO, Giordano</creator><general>Society for General Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100601</creationdate><title>Analysis of methods commonly used for glycopeptide and oxazolidinone susceptibility testing in Enterococcus faecium isolates</title><author>RAPONI, Giammarco ; CRISTINA GHEZZI, Maria ; GHERARDI, Giovanni ; LORINO, Giulia ; DICUONZO, Giordano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c364t-1d29977ea06755adaf4f1aeef5a921518748b82d8097abaa3a46131c5510be0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acetamides - pharmacology</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Bacterial Proteins - genetics</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>Carbon-Oxygen Ligases - genetics</topic><topic>DNA, Bacterial - genetics</topic><topic>Enterococcus faecium - drug effects</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glycopeptides - pharmacology</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Linezolid</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests - methods</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Oxazolidinones - pharmacology</topic><topic>Polymerase Chain Reaction</topic><topic>Polymorphism, Restriction Fragment Length</topic><topic>RNA, Ribosomal, 23S - genetics</topic><topic>Teicoplanin - pharmacology</topic><topic>Vancomycin - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RAPONI, Giammarco</creatorcontrib><creatorcontrib>CRISTINA GHEZZI, Maria</creatorcontrib><creatorcontrib>GHERARDI, Giovanni</creatorcontrib><creatorcontrib>LORINO, Giulia</creatorcontrib><creatorcontrib>DICUONZO, Giordano</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RAPONI, Giammarco</au><au>CRISTINA GHEZZI, Maria</au><au>GHERARDI, Giovanni</au><au>LORINO, Giulia</au><au>DICUONZO, Giordano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of methods commonly used for glycopeptide and oxazolidinone susceptibility testing in Enterococcus faecium isolates</atitle><jtitle>Journal of medical microbiology</jtitle><addtitle>J Med Microbiol</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>59</volume><issue>6</issue><spage>672</spage><epage>678</epage><pages>672-678</pages><issn>0022-2615</issn><eissn>1473-5644</eissn><coden>JMMIAV</coden><abstract>The susceptibility to teicoplanin, vancomycin and linezolid of 30 clinical isolates of Enterococcus faecium was tested by Vitek 2, Phoenix, Etest, broth microdilution and disc diffusion tests. The vanA and vanB resistance genes and the 23S rRNA gene G2576T mutation were detected by PCR and PCR-RFLP, respectively. Resistance rates to teicoplanin ranged from 3% for Vitek 2 to 57.6% for the Phoenix test, and those to vancomycin ranged from 56.7% for Vitek 2 to 86.7% for the Phoenix test. Only two out of 25 strains carrying the vanA gene were univocally recognized as the VanA phenotype. The only strain with the G2576T mutation did not carry the vanA gene and showed resistance to linezolid by the disc diffusion, Vitek 2 and broth dilution methods (MIC>8 microg ml(-1)), but was susceptible when tested with the Phoenix test and Etest (MIC<or=4 microg ml(-1)). Therefore, the resistance to glycopeptides and linezolid was not univocally detected by the susceptibility testing methods used in this study.</abstract><cop>Reading</cop><pub>Society for General Microbiology</pub><pmid>20185550</pmid><doi>10.1099/jmm.0.016444-0</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-2615 |
| ispartof | Journal of medical microbiology, 2010-06, Vol.59 (6), p.672-678 |
| issn | 0022-2615 1473-5644 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733118058 |
| source | MEDLINE; Microbiology Society; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Acetamides - pharmacology Anti-Bacterial Agents - pharmacology Bacterial Proteins - genetics Bacteriology Biological and medical sciences Carbon-Oxygen Ligases - genetics DNA, Bacterial - genetics Enterococcus faecium - drug effects Fundamental and applied biological sciences. Psychology Glycopeptides - pharmacology Humans Infectious diseases Linezolid Medical sciences Microbial Sensitivity Tests - methods Microbiology Miscellaneous Oxazolidinones - pharmacology Polymerase Chain Reaction Polymorphism, Restriction Fragment Length RNA, Ribosomal, 23S - genetics Teicoplanin - pharmacology Vancomycin - pharmacology |
| title | Analysis of methods commonly used for glycopeptide and oxazolidinone susceptibility testing in Enterococcus faecium isolates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T07%3A05%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20methods%20commonly%20used%20for%20glycopeptide%20and%20oxazolidinone%20susceptibility%20testing%20in%20Enterococcus%20faecium%20isolates&rft.jtitle=Journal%20of%20medical%20microbiology&rft.au=RAPONI,%20Giammarco&rft.date=2010-06-01&rft.volume=59&rft.issue=6&rft.spage=672&rft.epage=678&rft.pages=672-678&rft.issn=0022-2615&rft.eissn=1473-5644&rft.coden=JMMIAV&rft_id=info:doi/10.1099/jmm.0.016444-0&rft_dat=%3Cproquest_cross%3E733118058%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733118058&rft_id=info:pmid/20185550&rfr_iscdi=true |